



(51) International Patent Classification:

A61K 31/132 (2006.01) *A61K 31/397* (2006.01)
A61K 31/137 (2006.01) *A61P 37/00* (2006.01)
A61K 31/196 (2006.01)

(21) International Application Number:

PCT/EP2012/070692

(22) International Filing Date:

18 October 2012 (18.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/549,847 21 October 2011 (21.10.2011) US

(71) Applicant (for all designated States except US): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventor; and

(71) Applicant (for US only): **WALLSTROEM, Erik** [SE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agent: **HUTCHISON, John**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: DOSAGE REGIMEN FOR AN S1P RECEPTOR MODULATOR OR AGONIST

(57) Abstract: This invention relates to a method of treating multiple sclerosis in a mammalian patient, preferably a human, in need of such treatment, comprising administering to said human an S1P receptor modulator or agonist according to a dosing regimen that is determined with reference to the patient's blood lymphocyte count.



WO 2013/057212 A1